טוען...
Checkpoint inhibitors in the treatment of urological malignancies
Checkpoint inhibitors are monoclonal antibodies attach to several different receptors on T-cells or tumour cells expressing receptors for cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-1) and their ligand (PD-L1). Since 2010, numerous trials on different tumour types have been con...
שמור ב:
| הוצא לאור ב: | ESMO Open |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMJ Publishing Group
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5519795/ https://ncbi.nlm.nih.gov/pubmed/28761743 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000165 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|